AstraZeneca’s R&D Restructuring Follows Hot Spot Trend
This article was originally published in The Pink Sheet Daily
Executive Summary
In its most ambitious overhaul since the reorganization into iMeds in 2010, AstraZeneca’s latest R&D restructuring takes on three basic challenges: accessing innovation, improving internal productivity and reducing complexity and cost. It is the opening salvo in the new CEO’s vision for the troubled pharma.
You may also be interested in...
AstraZeneca Says Revamped Pipeline Will Return It To Health, But Pitfalls Remain
Equipped with 19 drug candidates for Phase III trials over the next two years, Britain’s AstraZeneca says it’s finally “on a roll.” But the troubled medicine maker still expects earnings to keep falling in 2014 amid uncertainty over heart drug Brilinta and likely generic competition to Nexium in the U.S.
Doubling Down On Cardiac Regeneration, AstraZeneca Forms Research Alliance With Shanghai SIBS
Going deeper into the cardiac regeneration space, AstraZeneca signed an agreement with SIBS to research coronary artery regeneration.
AstraZeneca’s Farxiga Label Includes, But Downplays, Bladder Cancer Risk
AstraZeneca’s SGLT-2 inhibitor Farxiga (dapagliflozin) finally clears FDA, and without a black box warning on bladder cancer risk – allowing the drug to compete with J&J’s first-to-market Invokana.